ACC: No doubt, PCSK9s work, but what's ahead?
This article was originally published in Scrip
Executive Summary
As anticipated, the PCSK9 inhibitors took center stage over this past weekend at the annual meeting American College of Cardiology's 63rd Annual Scientific Session in Washington, with Amgen's evolocumab, Pfizer's bococizumab and Sanofi's and Regeneron's alirocumab creating a lot of buzz.